Since their discovery, CD4+ CD25hiFOXP3hi regulatory T cells (Tregs) have been firmly
established as a critical cell type for regulating immune homeostasis through a plethora of …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

Immune rejection of allogeneic cell therapeutics remains a major problem for immuno-
oncology and regenerative medicine. Allogeneic cell products so far have inferior …

Allogeneic transplantation of pancreatic islets for patients with difficult-to-control diabetes
mellitus is severely hampered by the requirement for continuous immunosuppression and its …

Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome
many of the challenges associated with patient-derived (autologous) CAR T cells. Key …

Chimeric antigen receptor (CAR) T cells from allogeneic donors promise" off-the-shelf"
availability by overcoming challenges associated with autologous cell manufacturing …

Successful allogeneic human pluripotent stem cell (hPSC)-derived therapies must overcome
immunological rejection by the recipient. To build reagents to define these barriers, we …

The inability of the mammalian central nervous system (CNS) to undergo spontaneous
regeneration has long been regarded as a central tenet of neurobiology. However, while this …

Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …

Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are
promising cancer therapeutics that activate distinct arms of the immune system,. Here we …